Development and validation of a prognostic nomogram based on the clinical indicators for breast cancer

基于乳腺癌临床指标的预后列线图的建立与验证

阅读:1

Abstract

BACKGROUND: Breast cancer (BC) is one of the most prevalent malignancies among women worldwide, with heterogeneous outcomes necessitating individualized prognostic assessment. Existing models often rely on specialized biomarkers, limiting their accessibility in routine practice. This study aimed to develop and internally validate a prognostic nomogram based on readily available clinical indicators to predict overall survival (OS) in BC patients. METHODS: In this retrospective study, 217 BC patients diagnosed between 2012 and 2015 at The First Affiliated Hospital of Soochow University and The 904th Hospital of the Joint Logistics Support Force of the People's Liberation Army were enrolled. The cohort was randomly split into training and internal validation sets. Prognostic factors were selected using least absolute shrinkage and selection operator (LASSO) regression, followed by univariate and multivariate Cox regression analyses. A nomogram was constructed based on significant predictors from the training set. Its discriminative ability and calibration were evaluated using Harrell's concordance index (C-index), calibration curves, and time-dependent area under the curve (AUC). RESULTS: Six clinical indicators-hypertension, American Joint Committee on Cancer (AJCC) stage, metastasis, Ki-67 status, endocrine therapy, and red blood cell (RBC) count-were identified as independent prognostic factors and incorporated into the nomogram. The model demonstrated excellent discrimination, with a C-index of 0.898. In the training cohort, the AUCs for predicting 1-, 3-, and 5-year OS were 0.93, 0.89, and 0.93, respectively; corresponding values in the validation cohort were 0.98, 0.86, and 0.85. Calibration curves indicated good agreement between predicted and observed survival probabilities. CONCLUSIONS: We developed and validated a novel nomogram based on clinical indicators for predicting OS for BC, which showed good application prospect. This model has the potential to help in clinical decision-making and evaluating patient outcomes.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。